Black Diamond Therapeutics, Inc. BDTX is developing MasterKey therapies that target families of oncogenic mutations in ...

In recent research, treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically ...

NOTE. Percentage values in the cells may not sum up to 100% because of rounding. Bold indicates P < .05. Abbreviations: Bev, bevacizumab; ECOG-PS, Eastern Cooperative Oncology Group Performance Status ...

Timing and Outcomes of Palliative Care Integration Into Care of Adolescents and Young Adults With Advanced Cancer The advent of next-generation antibody-drug conjugates (ADCs), particularly ...

Presentation to include new patient-reported outcomes (PRO) data from the Phase 3 VERITAC-2 clinical trial –NEW HAVEN, Conn., ...

Eli Lilly and Company today announced results from the primary overall survival (OS) analysis of the Phase 3 monarchE trial showing that two years of adjuvant Verzenio plus endocrine therapy (ET) ...

Learn about HER2+ breast cancer, its aggressive nature, and the latest treatments available in India. Explore the impact of ...

Tucatinib enhances progression-free survival (PFS) in HER2+ metastatic breast cancer, showcasing promising results in a ...

Three presentations at ESMO 2025 will demonstrate Lunit SCOPE IO’s value in predicting immunotherapy response in colorectal, ...

US pharma major Eli Lilly has announced results from the primary overall survival (OS) analysis of the Phase III monarchE ...

Black Diamonds shares surge 86.4% in 2025 as strong silevertinib data and rising estimates fuel optimism for further gains.